Skip to main content
Clinical Trials/ITMCTR2100004789
ITMCTR2100004789
Recruiting
Phase 1

Clinical observation of fire needle combined with halometasone cream in the treatment of acral vitiligo

Dermatology Hospital,Southern Medical University0 sitesTBD
ConditionsVitiligo

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Vitiligo
Sponsor
Dermatology Hospital,Southern Medical University
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Dermatology Hospital,Southern Medical University

Eligibility Criteria

Inclusion Criteria

  • 1\. Meet the diagnostic criteria and consensus on diagnosis and treatment, meet the criteria for acral typing, meet the criteria for stable stage staging, and be stable for at least 6 months;
  • 2\. Aged 18 to 60 years, gender is not limited, the course of disease is less than 5 years;
  • 3\. There is no pigment island and self\-healing tendency in leukoplakia;
  • 4\. The skin lesion area accounts for \<\= 1% of the body surface area;
  • 5\. Have not received immunosuppressive agents, glucocorticoids, non\-steroidal anti\-inflammatory drugs and other systemic treatments within 3 months, and have not received local treatments within 1 month;
  • 6\. Patients who agree to and abide by the diagnosis and treatment plan, voluntarily sign an informed consent form, and cooperate in taking photos before and after treatment.

Exclusion Criteria

  • 1\. Fainted needles, scarred physique, or extremely fearful of fire needles;
  • 2\. Patients who are allergic to halometasone cream;
  • 3\. Patients with combined serious diseases, such as serious heart, brain, liver, kidney, hematopoietic system and other system diseases, or patients with malignant tumors;
  • 4\. Female patients who are pregnant, breastfeeding or planning to become pregnant within six months;
  • 5\. Partial skin lesions have redness, swelling, damage or infection.

Outcomes

Primary Outcomes

Not specified

Similar Trials